Skip to main content

Health condition

Liver fibrosis, caught early and treated at the source.

Scar tissue builds up quietly in the liver, often without symptoms. Non-invasive tests can stage it early - and treating the underlying cause can turn things around.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE NG50, BSG guidance and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK pathways including FibroScan, ELF testing and new pharmacotherapy for MASH-related fibrosis.

Key facts

Liver fibrosis at a glance.

The essentials, in plain English - what it is, what causes it, and how it’s staged and treated in the UK today.

  • What it is

    Excess scar tissue building up in the liver in response to chronic injury - a precursor to cirrhosis if it progresses unchecked.

  • Main causes

    MASLD/MASH, alcohol, chronic viral hepatitis B or C, autoimmune liver disease, haemochromatosis, PBC and PSC.

  • Staging

    Graded F0 (none) to F4 (cirrhosis) using the METAVIR or Ishak systems - the higher the stage, the more advanced the scarring.

  • Reversibility

    Early fibrosis can regress once the underlying cause is treated. Advanced fibrosis is harder to reverse but progression can still be slowed.

  • Presentation

    Usually silent until advanced - fatigue and vague symptoms only, often picked up through abnormal liver blood tests or risk-based screening.

  • First-line tests

    Non-invasive fibrosis scores (FIB-4, ELF test) come first, with FibroScan as the specialist-commissioned gold standard.

Why this guide matters

A silent process with a treatable cause.

Liver fibrosis rarely announces itself - which is exactly why the three points below matter so much.

  • It is usually silent until advanced

    Most people with fibrosis feel entirely well - detection depends on blood tests, risk-factor screening or incidental findings.

  • Non-invasive tests come first

    FIB-4 and the ELF test triage who needs a FibroScan, keeping biopsy for a small minority of unclear cases.

  • Treating the cause changes the outcome

    Whether it is weight, alcohol, a virus or iron, addressing the driver is what actually turns fibrosis around.

How the diagnosis is made

From an abnormal blood test to a clear stage.

The steps a UK GP or hepatologist will normally follow, per NICE NG50 - so you know what to expect and why.

  1. 01

    Screening

    Risk-factor and symptom review

    A history covering alcohol use, metabolic risk factors, viral exposure and family history, alongside any fatigue or vague right-upper-quadrant discomfort.

  2. 02

    Screening

    Standard liver blood tests

    ALT, AST, ALP, bilirubin and albumin - often the first clue when results are abnormal on a routine or risk-based screen.

  3. 03

    Screening

    FIB-4 score calculation

    A simple, non-invasive fibrosis score calculated from age, AST, ALT and platelet count - the recommended NICE NG50 first-line triage step.

  4. 04

    Staging

    ELF test if FIB-4 is indeterminate

    The Enhanced Liver Fibrosis test adds direct fibrosis markers when the FIB-4 result sits in a grey zone.

  5. 05

    Staging

    FibroScan (transient elastography)

    The specialist-commissioned gold-standard non-invasive test, measuring liver stiffness directly to stage fibrosis.

  6. 06

    Staging

    Cause-specific blood tests

    Viral hepatitis serology, autoantibodies and iron studies to pin down the underlying driver - specialist commissioned.

  7. 07

    Specialist

    MRI elastography or liver biopsy

    Reserved for selective cases where non-invasive results are unclear - MRI elastography or, rarely, biopsy as the reference standard.

  8. 08

    Specialist

    Hepatology MDT referral

    Advanced fibrosis, an unclear cause or discordant results are referred into specialist-commissioned hepatology care.

Typical timeline: non-invasive staging in weeks, with ongoing monitoring for the underlying condition.

Symptoms

What liver fibrosis actually feels like.

Mostly nothing at all in the early stages - and the features that mean it’s time to seek urgent care.

  • Often completely silent

    Most fibrosis, including moderate stages, causes no symptoms at all - it is found on blood tests or imaging done for another reason.

  • Fatigue

    A vague, persistent tiredness is the most commonly reported symptom, though it is non-specific and easy to dismiss.

  • Right-upper-quadrant discomfort

    A dull ache or fullness under the right ribs as the liver enlarges - more common as fibrosis advances.

  • Abnormal liver function tests

    Raised ALT or AST on a routine blood panel is often the first and only clue that prompts further fibrosis assessment.

  • Risk-factor screening pickup

    Increasingly detected through proactive screening in people with obesity, type 2 diabetes, heavy alcohol use or known hepatitis.

  • Itching and jaundice (later)

    Pruritus and yellowing of the skin or eyes suggest more advanced disease, including cholestatic conditions like PBC or PSC.

  • Spider naevi and palmar erythema

    Skin signs that become more visible as fibrosis progresses towards cirrhosis - worth flagging to your GP.

  • Red flag - signs of cirrhosis

    Ascites, confusion, bruising or vomiting blood signal decompensated disease and need urgent hepatology assessment.

Treatment

How liver fibrosis is treated in the UK.

Treating the underlying cause first, lifestyle change alongside it, and newer pharmacotherapy where it's indicated.

  • Treat the underlying cause

    The single most important step - antivirals for hepatitis B or C, alcohol cessation, immunosuppression for autoimmune disease or venesection for haemochromatosis. Specialist commissioned.

  • Weight loss for MASLD/MASH

    A 7 to 10% reduction in body weight through diet and exercise is proven to reduce liver fat and can reverse early fibrosis in metabolic liver disease.

  • Mediterranean diet and exercise

    A dietetics-supported lifestyle plan - reduced sugar and saturated fat, regular activity, and avoiding hepatotoxins including unnecessary supplements.

  • Resmetirom (Rezdiffra)

    A thyroid hormone receptor-beta agonist for MASH-related fibrosis, FDA-approved in 2024 - specialist commissioned for eligible patients.

  • GLP-1 receptor agonists

    Used for weight loss in MASLD/MASH, with emerging evidence of benefit on liver fat and fibrosis alongside metabolic improvement.

  • Serial fibrosis monitoring

    Repeat FibroScan or fibrosis blood scores at specialist-commissioned intervals to track whether the liver is stabilising, improving or progressing.

  • Hepatitis A and B vaccination

    Offered if not already immune, to protect a liver that is already under strain from further viral injury.

  • HCC surveillance once cirrhotic

    Six-monthly ultrasound surveillance for hepatocellular carcinoma is started once fibrosis has progressed to cirrhosis.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or hepatologist knows your history and results and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Cirrhosis in over 16s: assessment and management (NG50).

  • British Society of Gastroenterology (BSG). Guidelines on the assessment of liver fibrosis.

  • British Liver Trust. Patient information on liver fibrosis and cirrhosis.

  • US Food and Drug Administration. Approval summary for resmetirom (Rezdiffra) in MASH.

Red flags

When liver fibrosis needs urgent attention.

Most fibrosis is managed and monitored in the community or by outpatient hepatology. These signs mean that isn't enough.

  • Ascites

    New abdominal swelling from fluid accumulation signals decompensated liver disease and needs prompt hepatology assessment.

  • Jaundice

    Yellowing of the skin or eyes suggests significant liver dysfunction and should be assessed urgently.

  • Confusion or altered behaviour

    Possible hepatic encephalopathy from toxin build-up - needs urgent medical review, especially with known advanced fibrosis or cirrhosis.

  • Vomiting blood or black stools

    Suggests variceal bleeding from portal hypertension - a medical emergency requiring immediate hospital attendance.

  • Easy bruising or bleeding

    Reduced clotting factor production is a sign of significant liver impairment and warrants review.

  • Rapid weight loss or muscle wasting

    Can indicate decompensation or an undiagnosed complication and should prompt specialist reassessment.

  • New leg or ankle swelling

    Peripheral oedema alongside known liver disease can reflect worsening fluid balance and needs assessment.

  • Persistent fever with liver disease

    May indicate infection such as spontaneous bacterial peritonitis in someone with cirrhosis - needs same-day review.

  • Family history of unexplained liver disease

    Warrants proactive screening, particularly for haemochromatosis or autoimmune liver conditions.

Living with it

A condition you can genuinely turn around.

Four things that make the biggest difference day to day - treating the cause, eating well, staying on top of monitoring, and protecting the liver from further harm.

A quiet reminder

Early stages respond best - so don't wait to get checked.

The earlier fibrosis is found and the cause addressed, the more likely it is to genuinely regress.

  1. 01 Cause

    Treating the driver comes first

    Whatever is damaging the liver - alcohol, weight, a virus, autoimmunity or iron - addressing it gives the best chance of regression.

  2. 02 Diet

    Food choices matter every day

    A Mediterranean-style pattern, reduced sugar and alcohol avoidance genuinely change the trajectory of MASLD/MASH-related fibrosis.

  3. 03 Monitor

    Stay on top of monitoring

    Regular FibroScan or fibrosis blood tests catch progression early, while there is still time to intervene.

  4. 04 Avoid

    Protect the liver from extra harm

    Avoid unnecessary supplements, be cautious with over-the-counter medicines, and get vaccinated against hepatitis A and B if not already immune.

Frequently asked

Everything we get asked about liver fibrosis.

Quick answers on causes, staging, FibroScan and whether fibrosis can be reversed.

  • What is liver fibrosis?

    It is the build-up of excess scar tissue in the liver caused by chronic, ongoing injury. It sits on a spectrum from no scarring (F0) through to cirrhosis (F4), and is a precursor to cirrhosis if the underlying cause is not addressed.

  • What causes liver fibrosis?

    The most common causes in the UK are MASLD/MASH (metabolic-associated liver disease), heavy alcohol use, chronic hepatitis B or C infection, autoimmune liver disease, haemochromatosis, and cholestatic conditions such as PBC and PSC.

  • Can liver fibrosis be reversed?

    Early-stage fibrosis can regress once the underlying cause is properly treated - for example, weight loss in MASLD/MASH or antiviral treatment in hepatitis C. Advanced fibrosis is less reversible, but progression can still be slowed or halted.

  • How is liver fibrosis diagnosed without a biopsy?

    Most people are assessed with non-invasive tests first - a FIB-4 score from routine bloods, an ELF test if that result is unclear, and FibroScan (transient elastography) as the specialist-commissioned gold standard. Biopsy is reserved for selected, unclear cases.

  • What is FibroScan and do I need one?

    FibroScan is a quick, painless ultrasound-based test that measures liver stiffness to estimate the degree of fibrosis. It is specialist commissioned and typically arranged after an abnormal FIB-4 or ELF result, or for ongoing monitoring of a known liver condition.

  • Are there medicines for liver fibrosis?

    Treating the underlying cause remains the priority. For MASH-related fibrosis specifically, resmetirom (Rezdiffra) was approved in 2024 and GLP-1 agonists are increasingly used for associated weight loss - both specialist commissioned and used alongside lifestyle change, not instead of it.

Related content

Keep reading.